Researchmoz added Most up-to-date research on "OpportunityAnalyzer: Growth Hormone Deficiency - Opportunity Analysis and Forecasts to 2026" to its huge collection of research reports.
Growth hormone deficiency (GHD) is a rare endocrine disorder characterized by inadequate secretion of growth hormone (GH) from the anterior pituitary gland. It is a heterogeneous disorder that may present in childhood (pediatric GHD) or later in adult life (adult GHD). Reduced GH secretion predominantly results in stunted linear growth in children; therefore, the standard-of-care GH replacement therapy serves to normalize height in children. Adults with GHD generally demonstrate biochemical abnormalities, which can also be successfully treated with recombinant GH. GlobalData estimates the 2016 sales for GHD at approximately $1.42 billion across the 7MM covered in this report. The market will grow moderately at a CAGR of 3.9% during the 10-year forecast period, generating sales of approximately $2.08 billion at the end of 2026. The US market is expected to grow the fastest of the three regions, recording a CAGR of 4.4% and generating around 69% of global sales in 2026. This growth will be driven primarily by the highly anticipated arrivals of the long-acting GHs and the resultant increase in compliance with and adherence to therapy. Although the more convenient long-acting GHs are expected to markedly change the GHD treatment landscape, and eventually replace daily GHs, market growth will be restricted by the continued negotiations between distributers and payers, which is expected to keep the prices of these new drugs at bay.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1142783
Key Questions Answered
Overall, the greatest unmet need in the GHD space is the issue with treatment adherence and compliance. There are other prominent unmet needs highlighted by the Key Opinion Leaders (KOLs). What are these? Will the pipeline drugs fulfil these unmet needs of the market?
The 10-year forecast period will mark the launch of four pipeline long-acting GH drugs. How will the sales of the existing drugs be impacted? Which of the pipeline drugs will have the highest peak sales at the highest CAGR, and why?
What are the roles of payers in this highly competitive disease space? How does this affect market shares of the GH brands? What are the chances of reimbursement for the long-acting GH drugs in pipeline?
Scope
Overview of GHD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
Annualized GHD therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the GHD therapeutics market.
Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
Analysis of the current and future market competition in the global GHD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
Develop business strategies by understanding the trends shaping and driving the global GHD therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global GHD therapeutics market in future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the 7MM GHD therapeutics market from 2016-2026.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Companies mentioned
Novo Nordisk
Pfizer
Genentech/Roche
Ipsen SA
Eli Lilly
EMD Serono
Ferring
JCR Pharmaceuticals
Sandoz
LG Life Sciences
Biopartners GmbH
OPKO Health
Versartis Inc.
Ascendis
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Growth Hormone Deficiency: Executive Summary
2.1 GHD Market Will Exhibit Moderate Growth Between 2016 and 2026
2.2 Long-Acting Growth Hormones Will Fuel Market Growth and Improve the Treatment Landscape for GHD Patients
2.3 Payer Preferences Heavily Influence Market Shares of GH Drugs in the US
2.4 Disease Awareness and Stringent Regulatory and Insurance Policies Are Major Challenges in the GHD Market
2.5 Opportunities for New Entrants After the Launch of Long-Acting GHs Will Be Low During the Forecast Period
2.6 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Symptoms
4.3 Prognosis
4.4 Quality of Life
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 GHD in children
5.5 GHD in adults
5.6 Forecast Methodology
5.6.1 Sources
5.6.2 Forecast Assumptions and Methods
5.7 Epidemiological Forecast for GHD (2016-2026)
5.7.1 Diagnosed Prevalent Cases of GHD
5.7.2 Age-Specific Diagnosed Prevalent Cases of GHD
5.7.3 Sex-Specific Diagnosed Prevalent Cases of GHD
5.7.4 Idiopathic and Organic GHD in Children
5.7.5 Congenital and Acquired GHD Out of Organic GHD in Children
5.7.6 Idiopathic and Acquired GHD in Adults
5.7.7 Onset Timing
5.8 Discussion
5.8.1 Epidemiological Forecast Insight
5.8.2 Limitations of Analysis
5.8.3 Strengths of the Analysis
6 Current Treatment Options
6.1 Overview
6.2 Diagnosis and Treatment
6.2.1 Diagnosis
6.2.2 Treatment Guidelines and Leading Prescribed Drugs
6.3 Clinical Practice
6.4 Market Access and Reimbursement
6.5 Product Profiles – Recombinant Human Growth Hormones
6.5.1 Overview
6.5.2 Genotropin
6.5.3 Humatrope
6.5.4 Norditropin
6.5.5 Nutropin AQ
Continued...
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1142783
Growth hormone deficiency (GHD) is a rare endocrine disorder characterized by inadequate secretion of growth hormone (GH) from the anterior pituitary gland. It is a heterogeneous disorder that may present in childhood (pediatric GHD) or later in adult life (adult GHD). Reduced GH secretion predominantly results in stunted linear growth in children; therefore, the standard-of-care GH replacement therapy serves to normalize height in children. Adults with GHD generally demonstrate biochemical abnormalities, which can also be successfully treated with recombinant GH. GlobalData estimates the 2016 sales for GHD at approximately $1.42 billion across the 7MM covered in this report. The market will grow moderately at a CAGR of 3.9% during the 10-year forecast period, generating sales of approximately $2.08 billion at the end of 2026. The US market is expected to grow the fastest of the three regions, recording a CAGR of 4.4% and generating around 69% of global sales in 2026. This growth will be driven primarily by the highly anticipated arrivals of the long-acting GHs and the resultant increase in compliance with and adherence to therapy. Although the more convenient long-acting GHs are expected to markedly change the GHD treatment landscape, and eventually replace daily GHs, market growth will be restricted by the continued negotiations between distributers and payers, which is expected to keep the prices of these new drugs at bay.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1142783
Key Questions Answered
Overall, the greatest unmet need in the GHD space is the issue with treatment adherence and compliance. There are other prominent unmet needs highlighted by the Key Opinion Leaders (KOLs). What are these? Will the pipeline drugs fulfil these unmet needs of the market?
The 10-year forecast period will mark the launch of four pipeline long-acting GH drugs. How will the sales of the existing drugs be impacted? Which of the pipeline drugs will have the highest peak sales at the highest CAGR, and why?
What are the roles of payers in this highly competitive disease space? How does this affect market shares of the GH brands? What are the chances of reimbursement for the long-acting GH drugs in pipeline?
Scope
Overview of GHD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
Annualized GHD therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the GHD therapeutics market.
Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
Analysis of the current and future market competition in the global GHD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
Develop business strategies by understanding the trends shaping and driving the global GHD therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global GHD therapeutics market in future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the 7MM GHD therapeutics market from 2016-2026.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Companies mentioned
Novo Nordisk
Pfizer
Genentech/Roche
Ipsen SA
Eli Lilly
EMD Serono
Ferring
JCR Pharmaceuticals
Sandoz
LG Life Sciences
Biopartners GmbH
OPKO Health
Versartis Inc.
Ascendis
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Growth Hormone Deficiency: Executive Summary
2.1 GHD Market Will Exhibit Moderate Growth Between 2016 and 2026
2.2 Long-Acting Growth Hormones Will Fuel Market Growth and Improve the Treatment Landscape for GHD Patients
2.3 Payer Preferences Heavily Influence Market Shares of GH Drugs in the US
2.4 Disease Awareness and Stringent Regulatory and Insurance Policies Are Major Challenges in the GHD Market
2.5 Opportunities for New Entrants After the Launch of Long-Acting GHs Will Be Low During the Forecast Period
2.6 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Symptoms
4.3 Prognosis
4.4 Quality of Life
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 GHD in children
5.5 GHD in adults
5.6 Forecast Methodology
5.6.1 Sources
5.6.2 Forecast Assumptions and Methods
5.7 Epidemiological Forecast for GHD (2016-2026)
5.7.1 Diagnosed Prevalent Cases of GHD
5.7.2 Age-Specific Diagnosed Prevalent Cases of GHD
5.7.3 Sex-Specific Diagnosed Prevalent Cases of GHD
5.7.4 Idiopathic and Organic GHD in Children
5.7.5 Congenital and Acquired GHD Out of Organic GHD in Children
5.7.6 Idiopathic and Acquired GHD in Adults
5.7.7 Onset Timing
5.8 Discussion
5.8.1 Epidemiological Forecast Insight
5.8.2 Limitations of Analysis
5.8.3 Strengths of the Analysis
6 Current Treatment Options
6.1 Overview
6.2 Diagnosis and Treatment
6.2.1 Diagnosis
6.2.2 Treatment Guidelines and Leading Prescribed Drugs
6.3 Clinical Practice
6.4 Market Access and Reimbursement
6.5 Product Profiles – Recombinant Human Growth Hormones
6.5.1 Overview
6.5.2 Genotropin
6.5.3 Humatrope
6.5.4 Norditropin
6.5.5 Nutropin AQ
Continued...
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1142783
